Key result
Intramyocardial injection or intracoronary perfusion with rAAV vectors achieved stable transgene expression in up to 50% of murine cardiomyocytes at 4 to 8 weeks, whereas adenovirus was transient.
Why the study?
Does rAAV vector delivery provide stable transgene expression in murine cardiomyocytes compared to adenovirus vectors?
Does rAAV vector delivery provide stable transgene expression in murine cardiomyocytes compared to adenovirus vectors?
Direct intramyocardial injection or coronary artery perfusion with rAAV vectors enables stable, long-term transgene expression in cardiomyocytes without significant inflammation, overcoming limitations of adenovirus vectors.
No takes yet. Share an insight, caveat, or question.
May inform preclinical cardiac gene therapy strategies; leaves open translation to humans.
Svensson et al. (1999) studied this question. Recombinant adeno-associated virus (rAAV) vectors (AAVCMV-LacZ) vs. AdCMV-LacZ adenovirus vector was evaluated on beta-galactosidase (beta-gal) expression. Intramyocardial injection or intracoronary perfusion with rAAV vectors achieved stable transgene expression in up to 50% of murine cardiomyocytes at 4 to 8 weeks, whereas adenovirus was transient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: